Drugs that contain Delafloxacin Meglumine
1. Baxdela patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(1 year, 5 months from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(2 years from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(5 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(5 years from now) | |
| US8497378 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(5 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(1 year, 5 months from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(1 year, 5 months from now) | |
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(2 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
| New Indication(I-815) | Oct 24, 2022 |
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: TABLET;ORAL; POWDER;INTRAVENOUS
More Information on Dosage
BAXDELA family patents
